Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application (NDA) for TAK-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.1 The CRL indicates the FDA has completed its review of the TAK-721 NDA a

Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721

ENTYVIO's sales totaled about ¥130.5 billion in Q2 2021, up 4.1% quarter-on-quarter and 23.5% Q1 2020. Revenue for the company's key 14 medicines increased by 23.9% in the second quarter of 2021 compared to the previous quarter.

Takeda Pharmaceutical: Underappreciated Potential

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of intravenous (IV) vedolizumab for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC), and have had an inadequate

Takeda Receives Positive CHMP Opinion for Vedolizumab IV for the Treatment of Active Chronic Pouchitis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced the presentation of nine company-sponsored abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting being held December 11-14, 2021 in Atlanta, Georgia and virtually. The abstracts span Takeda's extensive hematology portfolio and research and development (R&D) pipeline, featuring data on multiple products and investigational candidates, supporting Takeda'

Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021

Petroleo Brasileiro

Royal Bank of Canada

If you want to increase your likelihood to discover value opportunities, one method is to screen the market for stocks with trailing 12-month price-to-free-cash-flow ratios lower than that of the S&P 500 Index, which stands at around 14.48 as of the writing of this article.

3 Stocks Trading With Low Price-to-Free-Cash-Flow Ratios

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold nearly 850,000 shares of Takeda Pharmaceutical Co.

Cathie Wood's ARK Invest Sells Nearly 850,000 Shares of Takeda Pharma

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the data from the pivotal Phase 3 SOLSTICE clinical trial of LIVTENCITY™ (maribavir, TAK-620) in post-transplant refractory† CMV infections with or without resistance‡ (R/R) were published in the journal of Clinical Infectious Diseases (CID). The manuscript is available online and will be included in a future print edition of CID, the official peer-reviewed

Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)

Halozyme Therapeutics

Longeveron

Prothena

Cassava Sciences Inc

Sesen Bio Inc.

Teva Pharmaceutical

These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared first on InvestorPlace.

7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present a total of 23 company-sponsored abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting being held December 11-14, 2021 in Atlanta, Georgia. Takeda's latest research in hematologic diseases focuses on optimizing patient care, while advancing novel approaches for patients with limited or ineffective treatment options. Takeda

Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the United States commercial availability of LIVTENCITY™ (maribavir), the first and only treatment for adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.1

Takeda's LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United States

Icahn Enterprises

Icahn Enterprises and Takeda Pharmaceutical are two intriguing hedges against sky-high inflation rates.

2 Ultra-High-Yield Dividend Stocks to Buy as a Hedge Against Inflation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it is enhancing its Corporate Social Responsibility (CSR) Program in the U.S., making an initial commitment of $20 million its first year supporting organizations in the U.S. to help improve equity among underrepresented communities in the areas of health, education, the environment and access to nutrition/food. Takeda also announced its current 2021 U.S. CSR Program gran

Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities

The FDA grants approval to the new drug application seeking approval for Takeda's (TAK) maribavir for treating post-transplant cytomegalovirus infection.

Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval

The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Livtencity (maribavir) for a common type of viral infection occurring in patients after organ transplant. The infection is caused by a type of herpes virus called cytomegalovirus (CMV).

Takeda's Maribavir Scores FDA Approval For Post-Transplant CMV Infection

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has approved LIVTENCITY™ (maribavir) for the treatment of adults and pediatric patients (12 years of age or older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofo

Takeda's LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 690,000 shares of Takeda Pharmaceutical Co.

Cathie Wood's ARK Invest Sells Over 690,000 Shares of Takeda Pharma

Takeda Pharmaceuticals Company ("Takeda"), a global, values-based, R&D-driven biopharmaceutical company, hosted the formal inauguration of the company's ICMEA* and Middle East Cluster Silver LEED Silver-certified** offices in Dubai World Trade Centre (DWTC), Dubai. Takeda Pharmaceuticals Company ("Takeda"), a global, values-based, R&D-driven biopharmaceutical company, hosted the formal inauguration of the company's ICMEA* and Middle East Cluster Silver LEED Silver-certified** offices in Dubai World Trade Centre (DWTC), Dubai.

Takeda's Area Offices in Dubai, United Arab Emirates Certified Sustainable and Inaugurated

Takeda owns a very large portfolio of major drugs and an even larger drug pipeline: the present and the future look secured. The stock has never been so cheap: that's why a share repurchase program was initiated.

Takeda Is Dirty Cheap: Great Opportunities Lie Ahead

CAMBRIDGE, Mass.--(BUSINESS WIRE)--As part of its commitment to reducing burdens facing the rare disease community, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced three priority policy reforms and solutions designed to address significant barriers to care for patients managing rare diseases and genetic conditions as part of a new report, “Reducing Time to Diagnosis for People Living with Rare Diseases: A Conversation on U.S. Policy Opportunities.” The propo

Takeda Recommends Common-sense Policy Reforms Designed to Reduce Time to Diagnosis, Improve Access to Care for Patients with Rare Disease

AbbVie

Bristol-Myers

Gilead Sciences

Merck

For years, one of the most dependable sectors, especially for more conservative investors, was health care, which included the top pharmaceutical and biotech stocks among other holdings.

5 Big Dividend Biotech and Pharmaceutical Stocks Have Strong Upside Potential

Weber

Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q2 2022 Results - Earnings Call Transcript

Takeda is just off the back of its first half numbers where revenue rose double digits and annual guidance was confirmed.

Takeda Pharmaceutical: Diversify Your Book With This Excellent Japanese Pharma Play

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) announced that its Board of Directors resolved today to engage in the acquisition of its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan, as detailed below. “At our current share price, we see an opportunity to buy back our shares at a substantial discount to what we perceive is their underlying valu

Takeda Announces Acquisition of Own Shares

Japan's Takeda Pharmaceutical Co said on Thursday that its half-year profit rose 61% as the drugmaker tries to wring synergies out of its acquisition of Shire Plc. Operating profit was 346 billion yen ($3.05 billion) in the six months through Sept.

Japan's Takeda half-year profit climbs, announces share buyback

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first half of fiscal year 2021 (period ended September 30, 2021). Based on the strong first half results, the company also confirmed its fiscal year 2021 management guidance. Fiscal year 2021, ending in March 31, 2022, continues to be a year of growth with anticipated topline acceleration driven by the company's 14 global brands. In addition, the compan

News for Takeda Pharmaceutical Stock (TAK)